Drug Promotion: FDA Loosens Reins But Industry Wants More Room To Run
Executive Summary
Agency proposes a safe harbor for certain communications with payers about approved uses and investigational drugs, but drug manufacturers ask the US agency to expressly protect from enforcement manufacturer communications about off-label uses.